These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31258078)

  • 1. Species Specificity on Interaction between IgE and FcεRI.
    Li X; Wang N; Zhao Y; Zhang Y; Liu Z
    Curr Pharm Biotechnol; 2019; 20(9):690-695. PubMed ID: 31258078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses.
    Zellweger F; Gasser P; Brigger D; Buschor P; Vogel M; Eggel A
    Allergy; 2017 Aug; 72(8):1174-1183. PubMed ID: 27997998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-specificity in the interaction of IgE with FcεRI between humans and rats.
    Li F; Wang N; Yang Y; Zhang S; Cui Z; Zhang Y; Liu Z
    Pharmazie; 2019 Jan; 74(1):29-33. PubMed ID: 30782247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation.
    Hong JY; Bae JH; Lee KE; Kim M; Kim MH; Kang HJ; Park EH; Yoo KS; Jeong SK; Kim KW; Kim KE; Sohn MH
    Yonsei Med J; 2016 Nov; 57(6):1412-9. PubMed ID: 27593869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Picture of Mast Cell Activation: The Complex Regulatory Network of High-Affinity Receptor for Immunoglobulin E Signaling.
    Suzuki R
    Biol Pharm Bull; 2017; 40(11):1828-1832. PubMed ID: 29093329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
    Gomez G
    Front Immunol; 2019; 10():175. PubMed ID: 30792720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular basis of allergy control].
    Gushchin IS
    Patol Fiziol Eksp Ter; 2005; (2):2-9. PubMed ID: 16078647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunoglobulin E-Toll-like receptor network.
    Novak N; Bieber T; Peng WM
    Int Arch Allergy Immunol; 2010; 151(1):1-7. PubMed ID: 19672091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils.
    Zellweger F; Buschor P; Hobi G; Brigger D; Dahinden CA; Villiger PM; Eggel A
    Cell Death Dis; 2018 May; 9(5):510. PubMed ID: 29724998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the FcepsilonRI beta-chain in allergic diseases.
    Kraft S; Rana S; Jouvin MH; Kinet JP
    Int Arch Allergy Immunol; 2004 Sep; 135(1):62-72. PubMed ID: 15316148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intrinsic flexibility of IgE and its role in binding FcepsilonRI.
    Harwood NE; McDonnell JM
    Biomed Pharmacother; 2007 Jan; 61(1):61-7. PubMed ID: 17188833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking the role of immunoglobulin E and its high-affinity receptor: new insights into allergy and beyond.
    Dema B; Suzuki R; Rivera J
    Int Arch Allergy Immunol; 2014; 164(4):271-9. PubMed ID: 25227903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Allergic Reactivity through Targeting FcεRI-Bound IgE with Humanized Low-Affinity Antibodies.
    Zhang K; Elias M; Zhang H; Liu J; Kepley C; Bai Y; Metcalfe DD; Schiller Z; Wang Y; Saxon A
    J Immunol; 2019 Dec; 203(11):2777-2790. PubMed ID: 31636239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro model for the allergen-IgE-FcARI interaction.
    Laffer S; Hogbom E; Adrianson J; Grönlund H; Sillaber C; Valent P; Vangelista L; Kricek F; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):116-8. PubMed ID: 10224355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of AMPK through Lyn-Syk-Akt enhances FcεRI signal pathways for allergic response.
    Lin KC; Huang DY; Huang DW; Tzeng SJ; Lin WW
    J Mol Med (Berl); 2016 Feb; 94(2):183-94. PubMed ID: 26373430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE signaling suppresses FcepsilonRIbeta expression.
    Brenzovich J; Macey M; Fernando J; Chong HJ; Barnstein B; Mirmonsef P; Morales JK; Kimura A; Cruz TD; Ryan JJ
    J Leukoc Biol; 2009 Dec; 86(6):1351-8. PubMed ID: 19741159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress in the understanding of IgE-FcepsilonRI interaction.
    Vangelista L
    Int Arch Allergy Immunol; 2003 Aug; 131(4):222-33. PubMed ID: 12915765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway].
    Liu ZC; Shi HL; Zhang YF; Zhao LJ
    Yao Xue Xue Bao; 2011 Oct; 46(10):1161-6. PubMed ID: 22242444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE.
    Laffer S; Hogbom E; Roux KH; Sperr WR; Valent P; Bankl HC; Vangelista L; Kricek F; Kraft D; Grönlund H; Valenta R
    J Allergy Clin Immunol; 2001 Sep; 108(3):409-16. PubMed ID: 11544461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated FcεRI triggering reveals modified mast cell function related to chronic allergic responses in tissue.
    Suurmond J; Habets KLL; Tatum Z; Schonkeren JJ; Hoen PAC'; Huizinga TWJ; Laros JFJ; Toes REM; Kurreeman F
    J Allergy Clin Immunol; 2016 Sep; 138(3):869-880. PubMed ID: 27033170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.